LEADER 01254nam 2200337 n 450 001 996385746903316 005 20200824121608.0 035 $a(CKB)4940000000071526 035 $a(EEBO)2240873251 035 $a(UnM)99839951e 035 $a(UnM)99839951 035 $a(EXLCZ)994940000000071526 100 $a19910122d1606 uy | 101 0 $alat 135 $aurbn||||a|bb| 200 00$aQuinti Horatii Flacci Poemata$b[electronic resource] $escholijs siue annotationibus, quę breuis commentarij vice esse possint a? Ioanne Bond illustrata 210 $aLondini $cExcudebat [R. Field for] Iohannes Norton, serenissimę Regi[a]e Maiestati in Latinis, Gręcis, & Hebraicis typographus$d1606 215 $a[12], 313, [1] p 300 $aA variant of the 1606 edition with George Bishop's name in the imprint, printed by R. Field (STC). 300 $aReproduction of the original in the Henry E. Huntington Library and Art Gallery. 330 $aeebo-0113 700 $aHorace$075513 701 $aBond$b John$f1550-1612.$021212 801 0$bCu-RivES 801 1$bCu-RivES 801 2$bCStRLIN 801 2$bWaOLN 906 $aBOOK 912 $a996385746903316 996 $aQuinti Horatii Flacci Poemata$92425057 997 $aUNISA LEADER 03268nam 2200673Ia 450 001 9910965645303321 005 20251117094457.0 010 $a0-19-174025-X 010 $a0-19-960737-0 010 $a1-283-34833-0 010 $a9786613348333 010 $a0-19-157581-X 035 $a(CKB)2550000000064626 035 $a(EBL)797725 035 $a(OCoLC)763157034 035 $a(SSID)ssj0000555589 035 $a(PQKBManifestationID)12244098 035 $a(PQKBTitleCode)TC0000555589 035 $a(PQKBWorkID)10519626 035 $a(PQKB)10355720 035 $a(MiAaPQ)EBC797725 035 $a(StDuBDS)EDZ0000091506 035 $a(Au-PeEL)EBL797725 035 $a(CaPaEBR)ebr10511371 035 $a(CaONFJC)MIL334833 035 $a(MiAaPQ)EBC7039287 035 $a(Au-PeEL)EBL7039287 035 $a(EXLCZ)992550000000064626 100 $a20100924d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aSystemic treatment of prostate cancer /$fedited by Alan Horwich 205 $a1st ed. 210 $aOxford ;$aNew York $cOxford University Press$d2010 215 $a1 online resource (102 p.) 225 1 $aOxford oncology library 300 $aDescription based upon print version of record. 311 08$a0-19-956142-7 320 $aIncludes bibliographical references and index. 327 $aContents; Preface; Symbols and abbreviations; Contributors; 1 Biological principles of hormone therapy; 2 PSA as a marker of progression and response in advanced prostate cancer; 3 Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer; 4 Systemic treatment of recurrence after local therapies; 5 First-line hormone therapy for metastatic prostate cancer; 6 Second- and third-line hormone therapies; 7 Chemotherapy for metastatic prostate cancer; 8 The role of bisphosphonates in the systemic treatment of prostate cancer; 9 Systemic isotope therapy of bone metastasis 327 $a10 Biological targets and new drug development for prostate cancerIndex; A; B; C; D; E; F; G; H; I; J; K; L; M; N; O; P; R; S; T; U; V; W; Z 330 $aProstate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r 410 0$aOxford oncology library. 606 $aProstate$xCancer$xDiagnosis 606 $aProstate$xCancer$xTreatment 615 0$aProstate$xCancer$xDiagnosis. 615 0$aProstate$xCancer$xTreatment. 676 $a616.9946306 701 $aHorwich$b Alan$01859943 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910965645303321 996 $aSystemic treatment of prostate cancer$94464317 997 $aUNINA